[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: Local control and toxicity profile after 24 months

Filippo Alongi, Stefano Schipani, Ana Maria Samanes Gajate, Alberto Rosso, Cesare Cozzarini, Claudio Fiorino, Pierpaolo Alongi, Maria Picchio, Luigi Gianolli, Cristina Messa, Nadia Di Muzio

Research output: Contribution to journalArticlepeer-review

Abstract

[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific antigen was undetectable and no late toxicities were recorded. A disease-free survival of 24 months, in the absence of any type of systemic therapy, is uncommon inmetastatic prostate cancer. The therapeutic approach of the case report is discussed and a literature review on the issue is presented.

Original languageEnglish
Pages (from-to)613-617
Number of pages5
JournalTumori
Volume96
Issue number4
Publication statusPublished - Jul 2010

Keywords

  • [C]choline-PET
  • Lymph node
  • Prostate
  • Relapse
  • Tomotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: Local control and toxicity profile after 24 months'. Together they form a unique fingerprint.

Cite this